FDA 483 - American National Red Cross (The) - September 13, 2010

This FDA Form 483 document outlines observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed three key deficiencies related to quality systems and manufacturing controls.

Observation 1 indicates that the firm failed to establish an adequate system for monitoring environmental conditions. This suggests a lack of control over the manufacturing environment, which could impact product quality and safety.

Observation 2 states that the firm did not adequately validate the cleaning process for manufacturing equipment. This is a critical finding as inadequate cleaning validation can lead to cross-contamination between different products or batches, posing significant risks to patient health.

Observation 3 highlights that the firm did not have proper documentation for the training of employees. This deficiency suggests a potential lack of trained personnel or, at minimum, a failure to maintain records demonstrating that employees are adequately trained for their roles, which is a fundamental requirement for Good Manufacturing Practices (GMP).

Collectively, these observations point to significant issues within the firm's quality management system, particularly concerning environmental control, equipment cleaning validation, and personnel training. Addressing these deficiencies is crucial for the firm to comply with regulatory requirements and ensure the quality and safety of its manufactured products.